363 related articles for article (PubMed ID: 30335946)
1. Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6.
McCoull W; Cheung T; Anderson E; Barton P; Burgess J; Byth K; Cao Q; Castaldi MP; Chen H; Chiarparin E; Carbajo RJ; Code E; Cowan S; Davey PR; Ferguson AD; Fillery S; Fuller NO; Gao N; Hargreaves D; Howard MR; Hu J; Kawatkar A; Kemmitt PD; Leo E; Molina DM; O'Connell N; Petteruti P; Rasmusson T; Raubo P; Rawlins PB; Ricchiuto P; Robb GR; Schenone M; Waring MJ; Zinda M; Fawell S; Wilson DM
ACS Chem Biol; 2018 Nov; 13(11):3131-3141. PubMed ID: 30335946
[TBL] [Abstract][Full Text] [Related]
2. Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
Cardenas MG; Yu W; Beguelin W; Teater MR; Geng H; Goldstein RL; Oswald E; Hatzi K; Yang SN; Cohen J; Shaknovich R; Vanommeslaeghe K; Cheng H; Liang D; Cho HJ; Abbott J; Tam W; Du W; Leonard JP; Elemento O; Cerchietti L; Cierpicki T; Xue F; MacKerell AD; Melnick AM
J Clin Invest; 2016 Sep; 126(9):3351-62. PubMed ID: 27482887
[TBL] [Abstract][Full Text] [Related]
3. Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein-Protein Interaction Interface.
Sameshima T; Yamamoto T; Sano O; Sogabe S; Igaki S; Sakamoto K; Ida K; Gotou M; Imaeda Y; Sakamoto J; Miyahisa I
Biochemistry; 2018 Feb; 57(8):1369-1379. PubMed ID: 29293322
[TBL] [Abstract][Full Text] [Related]
4. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.
McCoull W; Abrams RD; Anderson E; Blades K; Barton P; Box M; Burgess J; Byth K; Cao Q; Chuaqui C; Carbajo RJ; Cheung T; Code E; Ferguson AD; Fillery S; Fuller NO; Gangl E; Gao N; Grist M; Hargreaves D; Howard MR; Hu J; Kemmitt PD; Nelson JE; O'Connell N; Prince DB; Raubo P; Rawlins PB; Robb GR; Shi J; Waring MJ; Whittaker D; Wylot M; Zhu X
J Med Chem; 2017 May; 60(10):4386-4402. PubMed ID: 28485934
[TBL] [Abstract][Full Text] [Related]
6. Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6.
Kerres N; Steurer S; Schlager S; Bader G; Berger H; Caligiuri M; Dank C; Engen JR; Ettmayer P; Fischerauer B; Flotzinger G; Gerlach D; Gerstberger T; Gmaschitz T; Greb P; Han B; Heyes E; Iacob RE; Kessler D; Kölle H; Lamarre L; Lancia DR; Lucas S; Mayer M; Mayr K; Mischerikow N; Mück K; Peinsipp C; Petermann O; Reiser U; Rudolph D; Rumpel K; Salomon C; Scharn D; Schnitzer R; Schrenk A; Schweifer N; Thompson D; Traxler E; Varecka R; Voss T; Weiss-Puxbaum A; Winkler S; Zheng X; Zoephel A; Kraut N; McConnell D; Pearson M; Koegl M
Cell Rep; 2017 Sep; 20(12):2860-2875. PubMed ID: 28930682
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule-induced polymerization triggers degradation of BCL6.
Słabicki M; Yoon H; Koeppel J; Nitsch L; Roy Burman SS; Di Genua C; Donovan KA; Sperling AS; Hunkeler M; Tsai JM; Sharma R; Guirguis A; Zou C; Chudasama P; Gasser JA; Miller PG; Scholl C; Fröhling S; Nowak RP; Fischer ES; Ebert BL
Nature; 2020 Dec; 588(7836):164-168. PubMed ID: 33208943
[TBL] [Abstract][Full Text] [Related]
8. PROTAC-mediated crosstalk between E3 ligases.
Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of
Guo W; Xing Y; Zhang Q; Xie J; Huang D; Gu H; He P; Zhou M; Xu S; Pang X; Liu M; Yi Z; Chen Y
J Med Chem; 2020 Jan; 63(2):676-695. PubMed ID: 31895575
[TBL] [Abstract][Full Text] [Related]
10. The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.
Cardenas MG; Oswald E; Yu W; Xue F; MacKerell AD; Melnick AM
Clin Cancer Res; 2017 Feb; 23(4):885-893. PubMed ID: 27881582
[TBL] [Abstract][Full Text] [Related]
11. An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo.
Xing Y; Guo W; Wu M; Xie J; Huang D; Hu P; Zhou M; Zhang L; Zhang Q; Wang P; Wang X; Wang G; Wu H; Zhou C; Chen Y; Liu M; Yi Z; Sun Z
Cancer Lett; 2022 Mar; 529():100-111. PubMed ID: 34990752
[TBL] [Abstract][Full Text] [Related]
12. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W
Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291
[TBL] [Abstract][Full Text] [Related]
13. Identification BCL6 and miR-30 family associating with Ibrutinib resistance in activated B-cell-like diffuse large B-cell lymphoma.
Li J; Huang Y; Zhang Y; Wen J; Chen Y; Wang L; Jiang P; Hu J
Med Oncol; 2021 Feb; 38(4):33. PubMed ID: 33629212
[TBL] [Abstract][Full Text] [Related]
14. Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.
Ai Y; Hwang L; MacKerell AD; Melnick A; Xue F
J Med Chem; 2021 Apr; 64(8):4333-4358. PubMed ID: 33844535
[TBL] [Abstract][Full Text] [Related]
15. Wilms' tumor 1-associating protein plays an aggressive role in diffuse large B-cell lymphoma and forms a complex with BCL6 via Hsp90.
Kuai Y; Gong X; Ding L; Li F; Lei L; Gong Y; Liu Q; Tan H; Zhang X; Liu D; Ren G; Pan H; Shi Y; Berberich-Siebelt F; Mao Z; Zhou R
Cell Commun Signal; 2018 Aug; 16(1):50. PubMed ID: 30143009
[TBL] [Abstract][Full Text] [Related]
16. Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design.
Cheng H; Linhares BM; Yu W; Cardenas MG; Ai Y; Jiang W; Winkler A; Cohen S; Melnick A; MacKerell A; Cierpicki T; Xue F
J Med Chem; 2018 Sep; 61(17):7573-7588. PubMed ID: 29969259
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
18. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).
Kang CH; Lee DH; Lee CO; Du Ha J; Park CH; Hwang JY
Biochem Biophys Res Commun; 2018 Oct; 505(2):542-547. PubMed ID: 30274779
[TBL] [Abstract][Full Text] [Related]
19. Discovery of an
Harnden AC; Davis OA; Box GM; Hayes A; Johnson LD; Henley AT; de Haven Brandon AK; Valenti M; Cheung KJ; Brennan A; Huckvale R; Pierrat OA; Talbot R; Bright MD; Akpinar HA; Miller DSJ; Tarantino D; Gowan S; de Klerk S; McAndrew PC; Le Bihan YV; Meniconi M; Burke R; Kirkin V; van Montfort RLM; Raynaud FI; Rossanese OW; Bellenie BR; Hoelder S
J Med Chem; 2023 Apr; 66(8):5892-5906. PubMed ID: 37026591
[TBL] [Abstract][Full Text] [Related]
20. A Critical Role of miR-144 in Diffuse Large B-cell Lymphoma Proliferation and Invasion.
Wang H; Wang A; Hu Z; Xu X; Liu Z; Wang Z
Cancer Immunol Res; 2016 Apr; 4(4):337-44. PubMed ID: 26865454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
